Kwon to lead Alchemab as Treco departs

Chief Financial and Operating Officer Young Kwon will become CEO and a director of  Alchemab Therapeutics Ltd. following the departure of Douglas Treco, who resigned for personal reasons. Kwon joined the antibody company in November from Momenta Pharmaceuticals Inc., where he was chief financial and business officer.

Drew Young became chief commercial officer and head of patient experience at Anthos Therapeutics Inc., a cardiovascular and metabolic disease company.  Young, a veteran of Bristol Myers Squibb Co. (NYSE:BMY), was most recently a commercial consultant at Anthos...